Page 95 - NobleCon20-Book-Project

IN8bio, Inc.

SELECTED FINANCIAL ITEMS INAB

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (7.93) (8.65) (8.69) (6.04) (31.30)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (7.60) (8.56) (8.63) (7.09) (31.88)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 33.71 25.55 22.50 15.97 15.97
Cash & Short Term Investments 21.28 13.02 10.22 4.00 4.00
% of Assets 63% 51% 45% 25% 25%
Current Assets -Total 24.63 15.76 12.68 6.70 6.70
% of Assets 73% 62% 56% 42% 42%
Total Liabilities 8.77 8.02 8.88 7.38 7.38
% of Assets 26% 31% 39% 46% 46%
Current Liabilities - Total 5.39 3.84 4.76 3.64 3.64
% of Assets 16% 15% 21% 23% 23%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 24.94 17.53 13.62 8.59 8.59
% of Assets 74% 69% 61% 54% 54%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (4.85) (7.92) (6.09) (6.11) (24.97)
Net Cash Flow - Investing (0.07) (0.07) (0.08) 0.00 (0.23)
Net Cash Flow - Financing 13.35 (0.28) 3.38 (0.11) 16.35

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference